Illumina, Inc.
http://www.illumina.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Illumina, Inc.
Spotting Zebras: Technology Cutting Through The Diagnostic Odyssey
Software and genetic sequencing hold promise in detecting and treating rare diseases, two experts told Medtech Insight.
Deal Watch: Aging-Focused Calico Taps Start-Up Terray For Discovery
Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.
Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
Stock Watch: Different Regulators Bare Their Teeth At Biotech
When the sector worries about regulation it is usually about drug development and registration. But governments also regulate on monopolistic positions in life sciences. Adding to that, national security enforcement is now rising.
Company Information
- Industry
- Pharmaceuticals
- Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- GenoLogics Life Sciences Software
- GRAIL Inc.
- Myraqa
- Verinata Health
- Illumina Ventures